Cancer Immunotherapy
Recombinant xenogeneic endoglin boosts immune system response to tumors
Published in Cancer Weekly, September 14th, 2004
"Angiogenesis plays a critical role in tumor growth and metastasis. Increasing evidence suggests that endoglin is a powerful marker of angiogenesis in solid malignancies. Thus, breaking of immune tolerance of self-endoglin-associated angiogenesis is an attractive approach to cancer therapy," scientists writing in the European Journal of Immunology report.
"To test this concept, we recombined the extracellular domains of porcine endoglin, and used it as a xenogeneic vaccine. We found that immunotherapy with porcine endoglin was effective at both protective and therapeutic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-09-14)
More Articles from Cancer Weekly
- Bladder Cancer
E2F3 amplification associated with invasive disease - Cancer Diagnosis
Serum complexes bolster the detection of primary liver cancer - Cancer Therapy
FDA approves Alimta for second-line treatment of advanced lung cancer - Oncogenesis
Leukocyte cell-derived chemotaxin 2 is central to liver cancer formation - Viral Proteomics
Hepatitis B virus X protein increases the invasive potential of liver cancer - Aspergillosis
Mode rate doses of corticosteroids increase invasive aspergillosis risk in ASCT - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
